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Objective: To determine if APOE-ε4 influences the association between white matter 
hyperintensities (WMH) and cognitive impairment in Alzheimer’s disease (AD) and dementia 
with Lewy bodies (DLB). 
Methods: 289 patients (AD=239; DLB=50) underwent volumetric MRI, neuropsychological 
testing, and APOE-ε4 genotyping. Total WMH volumes were quantified. Neuropsychological 
test scores were included in a confirmatory factor analysis (CFA) to identify cognitive domains 
encompassing attention/executive functions, learning/ memory, and language, and factor scores 
for each domain were calculated per participant. After testing interactions between WMH and 
APOE-ε4 in the full sample, we tested associations of WMH with factor scores using linear 
regression models in APOE-ε4 carriers (n=167) and non-carriers (n=122). We hypothesized that 
greater WMH volume would relate to worse cognition more strongly in APOE-ε4 carriers. 
Findings were replicated in 198 AD patients from the Alzheimer’s Disease Neuroimaging 
Initiative (ADNI-I), and estimates from both samples were meta-analyzed. 
Results: A significant interaction was observed between WMH and APOE-ε4 for language, but 
not for memory or executive functions. Separate analyses in APOE-ε4 carriers and non-carriers 
showed that greater WMH volume was associated with worse attention/executive functions, 
learning/memory, and language in APOE-ε4 carriers only. In ADNI-I, greater WMH burden was 
associated with worse attention/executive functions and language in APOE-ε4 carriers only. No 
significant associations were observed in non-carriers. Meta-analyses showed that greater WMH 





Conclusion: APOE-ε4 may influence the association between WMH and cognitive performance 
in patients with AD and DLB. 
Keywords: APOE-ε4, Alzheimer’s disease, Dementia with Lewy bodies, white matter 






White matter hyperintensities (WMH) observed on structural MRI indicate cerebral small vessel 
disease (SVD) in most cases,1 are risk factors for cognitive impairment and Alzheimer’s disease 
(AD),2,3 and are prevalent in dementia with Lewy bodies (DLB).4,5 However, observed cognitive 
performance clinically does not always reflect the severity of the WMH burden.6,7 
There are several reasons for the complex association between WMH and cognition: the etiology 
of WMH is heterogeneous, including vascular compromise and ischemia, venous collagenosis, 
leading to vasogenic edema,8,9 cerebral amyloid angiopathy (CAA), or a combination of these,10 
and genetic vulnerability to neurodegeneration. 
The APOE-ε4 allele is the strongest known genetic risk factor for sporadic AD, and is a risk 
factor for DLB11,12, CAA,13 and SVD.14 Despite these associations, it remains unknown if 
APOE-ε4 modulates the relationship between WMH and cognition across the dementias, i.e. if 
APOE-ε4 is an effect modifier in this association. 
Therefore, we examined the role of APOE-ε4 on the association between WMH and cognitive 
domains in AD and DLB patients with varying degrees of SVD. We tested associations with 
domain-specific cognitive impairment instead of global cognition because at different disease 
stages, impairment might be more apparent in certain domains and not others. We hypothesized 
that (i) higher WMH burden would be more strongly associated with worse cognition in APOE-
ε4 carriers than non-carriers and the association would be APOE-ε4 allele dosage dependent, (ii) 
this association would be irrespective of the clinical diagnosis, and (iii) if indeed WMH burden is 
associated with worse cognition in APOE-ε4 carriers, WMH in carriers might be a result of a 





This is a cross-sectional study examining the effect of APOE-ε4 on the association of WMH 
volume and cognitive functions in patients with AD and DLB. 
Setting 
This work was embedded within the Sunnybrook Dementia Study (SDS)– a prospective 
observational study of dementia patients.15 The majority of participants in the SDS are Caucasian 
of European descent. 
For replication of study findings, data from the Alzheimer’s Disease Neuroimaging Initiative-
Phase I (ADNI-I) (2002-2004) were utilized (adni.loni.usc.edu).16 ADNI was launched in 2003 
as a public-private partnership. For the most up to date information, please see www.adni-
info.org.  
ADNI-I is characterized by a low WMH burden (<10 cm3) at recruitment and cognitive 
impairment is largely attributed to AD pathology with minimal confounding comorbid SVD. The 
SDS represents a heterogeneous “real-world” clinical case series followed longitudinally, and 
reflects a similar vascular risk factor and SVD burden profile to community and population-
based studies.17 
 
Standard Protocol Approvals, Registrations, and Patient Consents 
SDS (ClinicalTrials.gov: NCT01800214) is approved by the local Research Ethics Board at 
Sunnybrook Health Sciences Centre and written informed consent was obtained from 




Study samples  
SDS sample: Data from 289 MRI-confirmed stroke-free dementia patients, including APOE-ɛ4 
genotype, MRI volumetrics and neuropsychological battery were available. This included 239 
AD and 50 DLB patients with varying degrees of SVD. Of the 289 patients included, 36 had 
autopsy data available. 
ADNI-I (Replication sample): 198 AD patients with APOE-ɛ4 genotype, MRI volumetric and 
neuropsychological data available were included. We used data from the 24 month follow-up 
visit instead of baseline for better comparability to the SDS sample given the mild initial nature 
of participants included in ADNI, i.e. progression of the AD stage and that of WMH burden, and 
ensuring a sufficient number of participants to obtain valid estimates. 
 
Diagnosis of dementia 
For both study samples, AD was diagnosed on recruitment, using the Neurological and 
Communicative Disorders and Stroke and the Alzheimer’s Disease and Related Disorders 
Association (NINCDS-ADRDA) criteria,18 while DLB (SDS only) was diagnosed using the 
Third Report of DLB Consortium criteria.19 Diagnoses were confirmed on clinical follow-up. 
Diagnostic consensus in the SDS was achieved through review by at least two physicians (MM, 






APOE genotyping was performed using DNA extracted from leukocytes in both the SDS20 and in 
ADNI.21 Genotype frequencies in both samples did not deviate from that predicted by Hardy-
Weinberg equilibrium. 
 
MRI (White matter hyperintensity volume) 
SDS sample: MRI scans were acquired on a 1.5-Tesla Signa system (GE Healthcare, Milwaukee, 
WI). Three sets of structural MRI sequences were used: T1-weighted, T2-weighted, and proton-
density weighted (PD). Details of MRI acquisition are provided elsewhere.15 
MRIs were processed using the Semi-Automated Brain Region Extraction and Lesion Explorer 
processing pipeline.22 WMHs were identified as lesions that appear as punctate or diffuse regions 
of hyperintense signal on T2/PD MRI. These images were used to quantify global, deep and 
periventricular WMH volumes (cm3). For analyses, total WMH volumes adjusted for total 
intracranial volume (TIV) were used: TIV adjusted WMH volumes = (raw WMH volume/TIV) × 
103. 
ADNI-I (Replication sample): Methods for MRI data acquisition, processing, and WMH 
quantification are described in detail elsewhere.23  
 
Neuropsychological test battery 
SDS sample: The neuropsychological battery was performed within 90 days of MRI acquisition. 
Trained psychometrists blinded to neuroimaging, dementia diagnosis, and genotype information 




were administered: (1) Mini-Mental State Examination (MMSE), (2) Dementia Rating Scale 
(DRS), (3) California verbal Learning Test (CVLT), total acquisition score through five trials, 
CVLT long delay-free recall, and CVLT long delay-cued recall (4) Wechsler Memory Scale 
(WMS) visual recognition immediate and delayed recall, (5) forward digit span (FDS) (6) 
backward digit span (BDS), (7) Boston naming (BN) and (8) Semantic Fluency (SF), (9) 
Wisconsin Card Sorting test (WCST), (10) Controlled Oral Word Association task-Phonemic 
Fluency (PF-FAS), (11) Trail making test A, and (12) Digit Symbol substitution task (DSST). 
The number of patients who completed each test differed; this variability was dependent on 
dementia severity. 90% of patients had completed at least 8 neuropsychological tests. 
ADNI-I (Replication sample): The cognitive test battery in ADNI-1 included (1) MMSE (2) Rey 
Auditory verbal learning test (RAVLT)-total acquisition score through five trials and delayed 
recall, (3) logical memory immediate and delayed recall, (4) FDS (5) BDS, (6) BN (7) category 
fluency (animals and vegetables), (8) Trail Making test A, and (9) DSST. Details are described 
elsewhere.25 
For all test scores, higher scores correspond to better cognition, except for WCST (number of 
non-perseverative errors; SDS only), and Trail making test A (time taken to complete the task in 
seconds), for which a higher score corresponds to worse performance. 
 
Covariates 
SDS sample: Age, sex, years of education, diabetes mellitus type 2 (present vs absent), systolic 




past or current smoking), and dementia diagnosis (AD or DLB) were considered potential 
confounders. 
ADNI-I (Replication sample): Available covariates in ADNI-I included age, sex, education, and 
systolic and diastolic blood pressure. 
For consistency across both study samples, we included systolic and diastolic blood pressure as 
covariates and not hypertension. 
 
Neuropathology methods in SDS (Exploratory sample) 
36 of the SDS cases had a post-mortem neuropathological examination  to diagnose and stage 
neurodegenerative disease phenomena.15 This workup included a screen for CAA using 
immunohistochemistry for beta-amyloid (Dako manufacturer, Mach 4 detection system) in at 
least two brain sections (cerebellum and frontal cortex). For 34 of these 36 cases, the original 
autopsy reports were reviewed by a neuropathologist (JK) to determine the presence or absence 
of CAA. For two of the 36 cases, the reports were not available. For three of the 34 cases with 
available reports, the presence or absence of amyloid angiopathy was not stated in the autopsy 
report; the slides from the original autopsy were retrieved, reviewed by JK, and the presence or 
absence of CAA was determined. Given that only two anatomical areas of the brain had been 
screened for CAA, applying a formal CAA grading scheme was not feasible. Using these data 





TIV adjusted WMH volumes were log-transformed to achieve a normal distribution and 
standardized by calculating z-scores. 
We compared participant characteristics between APOE-ɛ4 carriers and non-carriers using t-tests 
for continuous and Chi-squared tests for categorical variables.  
Confirmatory factor analysis and regression: In both samples, we aimed to reduce the number of 
tests by making comprehensive factor scores (latent constructs) for each cognitive domain, based 
on the specific tests and the domain that they are known to assess. Therefore, we conducted a 
Confirmatory Factor Analysis (CFA)26 and calculated scores for each cognitive factor, i.e. 
attention/executive functions, learning/memory, and language for each participant. These 
cognitive factor scores were then used as outcomes in our analyses instead of individual test 
scores. CFA uses all available information for any model specified instead of a complete case 
analysis, and obtained factors are allowed to correlate. We present standardized parameters in 
this paper to facilitate interpretation. Adequacy of model fit to the data was assessed by 
Comparative fit index (CFI- range: 0-1; recommended ≥ 0.95), Root Mean Square Error of 
Approximation (RMSEA-range 0-1; recommended ≤ 0.06), and the Standardized Root Mean 
Square Residual (SRMR-range 0-1; recommended ≤ 0.08).27 
Subsequently, in both study samples, we first tested associations between WMH volume and 
each of the three cognitive factor scores with all covariates including APOE-ɛ4 carrier status as a 
predictor, and also tested the interaction between WMH and APOE-ɛ4 carrier status. 
Second, we investigated the associations between WMH volume and each cognitive factor score 




WMH burden would be more strongly associated with worse cognition in APOE-ε4 carriers than 
non-carriers, because of the known strong biological effects of the APOE-ε4 allele.28 
SDS sample: Relationships between the following cognitive factors and observed test scores 
were hypothesized and tested using CFA: (1) attention/executive functions [FDS, BDS, Trails A, 
WCST-perseverative errors, PF-FAS, and DSST], (2) learning/memory [CVLT-total acquisition 
score-trials 1-5, CVLT-long delay free and cued recall, WMS-immediate recall, and delayed 
recall], and (3) language [BN, SF, PF-FAS]. Scores for WCST and Trails A were inverse-coded 
for consistency with other test scores. 
We used the following multiple linear regression model in the SDS sample (N=289) to test 
associations of WMH with executive functions, memory, and language, and an interaction 
between WMH and APOE-ɛ4 carrier status: 
Cognitive factor score =β0 + β1* WMH volume + β2*APOE-ε4 carrier status+ β3*(WMH 
volume x APOE-ε4 carrier status) + β4*age + β 5*sex + β6*education + β7*diabetes mellitus + 
β8*systolic blood pressure + β9*diastolic blood pressure + β10*smoking + β11*clinical 
dementia diagnosis 
Further, we tested associations of WMH with the cognitive domains in APOE-ε4 carriers and 
non-carriers separately using a similar model, but without APOE-ε4 and its interaction term. 
For each regression, two models were fitted. Model I was adjusted for age and sex; II was 
additionally adjusted for years of education, diabetes mellitus type 2, systolic and diastolic blood 
pressure, smoking status, and dementia diagnosis. We also repeated model II by replacing 




The following variables had missing values and were dealt with by multiple imputation using 
chained equations in Stata: systolic and diastolic blood pressure and smoking (2.8%, n=8), 
diabetes (3.1%, n=9), and years of education (0.3%, n=1). All available covariates were used as 
predictors for imputation. 
Since studies suggest that WMH are not associated with cognition in DLB, but in AD only,4,29 
we repeated the analyses in APOE-ɛ4 carriers and non-carriers excluding DLB cases. 
In a post-hoc analysis, we tested if associations between WMH and cognitive domains in APOE-
ɛ4 carriers were dependent on APOE-ɛ4 allele dosage. After comparing study characteristics and 
WMH volumes by APOE-ɛ4 allele dosage (0, 1 or 2 alleles) using ANOVA (Tukey post-hoc) and 
Chi-squared tests for continuous and categorical variables respectively, we repeated our analyses 
in APOE-ɛ4 heterozygotes (n=130) and APOE-ɛ4 homozygotes (n=37). 
Exploratory neuropathology sample-SDS: 
We explored the prevalence of CAA by APOE-ɛ4 carrier status in our autopsy subsample (n=34). 
This analysis was conditional on our primary results, i.e., to be performed if indeed WMH were 
associated with worse cognition more strongly in APOE-ε4 carriers than non-carriers. In this 
case, we hypothesized that since APOE-ε4 is a risk factor for CAA, the likely etiology of WMH 
in carriers is CAA which might be more toxic than WMH caused by vascular compromise or 
ischemia due to cardiovascular risk factors alone. We compared the numbers of patients with 
CAA by APOE-ɛ4 carrier status and by allele dosage using Fisher’s exact test. Since studies 
suggest that CAA is more prevalent in APOE-ɛ2 carriers,30 we also examined the number of 
persons with CAA across genotypes: ɛ2- ɛ3 (n=2), ɛ3-ɛ3 (n=12), ɛ3-ɛ4 (n=13), and ɛ4-ɛ4 (n=7), 




ADNI-I (Replication sample): Relationships between the following cognitive factors and 
observed test scores were hypothesized and tested: (1) attention/executive [FDS, BDS, Trails 
making test A (inverse-coded), and DSST], (2) learning/memory [RAVLT-trials 1-5 (immediate 
recall), RAVLT-delayed recall, and logical memory immediate and delayed recall], and (3) 
language [BN, category fluency- animals, and category fluency-vegetables]. 
As in the SDS, a full model with and interaction term (WMH x APOE-ɛ4) was tested (full 
ADNI-1 sample; N=198), and then analyses were repeated in APOE-ɛ4 carriers and non-carriers 
separately. For regression, model I was adjusted for age and sex only; II was additionally 
adjusted for education, and systolic and diastolic blood pressure. Analyses were also repeated in 
APOE-ɛ4 heterozygotes (n=91) and homozygotes (n=40). 
Since power was limited in both our study samples, we meta-analyzed the beta-coefficients from 
SDS and ADNI-I for all three cognitive scores to obtain more robust estimates.31 This was done 
using the metan command in Stata,32 which uses inverse variance weighting method. 
Level of significance was set at 0.05 (two-sided) for all statistical tests, and all analyses were 
performed using the Stata Software Version 14.1 (StataCorp, College Station, TX, USA). 
Data availability statement 
The authors have carefully documented all data, methods, and materials used to conduct the 








Characteristics of the study sample are presented in Table 1. Participant characteristics or WMH 
volumes did not differ between APOE-ε4 carriers and non-carriers. Table 2 summarizes the 
neuropsychological test scores by APOE-ε4 carrier status. 
In the CFA, single confirmatory factor models for all three cognitive factors tested showed 
excellent fit to the data: attention/executive (CFI=0.98; RMSEA=0.04; SRMR=0.03); 
learning/memory (CFI=0.99, RMSEA=0.04, SRMR=0.009); and language (CFI=1.00, RMSEA= 
<0.0001, SRMR= <0.0001). 
In the full model (N=289), WMH volume was not associated with attention/executive functions, 
learning/memory or language. An interaction between WMH and APOE-ε4 (p-value 0.02) was 
observed for language, but not for executive functions (p-value 0.26) or memory (p-value 0.11). 
With our a priori hypothesis that WMH relate to cognition differently in carriers and non-
carriers, and a significant interaction observed between WMH and APOE-ε4 for language, we 
performed analyses separately in APOE-ε4 carriers and non-carriers for all cognitive domains. 
In these analyses, greater WMH volumes were associated with worse attention/executive 
functions, learning/memory, and language in only APOE-ε4 carriers; no associations were 
observed in non-carriers (Table 3). Replacing blood pressure with hypertension did not change 
results. 
After excluding patients with DLB (n=50), a similar pattern of results was obtained (Table 4). 
Homozygous APOE-ε4 carriers were younger than non-carriers and heterozygous carriers 




non-carriers and heterozygous carriers (ANOVA p-value =0.002). Heterozygous carriers had a 
greater burden of cardiovascular risk factors (Table 1).WMH were related to worse 
attention/executive functions (difference per SD: -0.23; 95% CI: -0.41, -0.04), learning /memory 
(difference per SD: -1.39; 95% CI: -2.51, -0.26), and language (difference per SD: -0.90; 95% 
CI:-1.59, -0.22) in APOE-ε4 heterozygotes only, and not in homozygotes: (difference in 
attention/executive score per SD: 0.06; 95% CI: -0.37, 0.49; difference in learning/memory score 
per SD: 0.21; 95% CI: -2.21, 2.63; difference in language score per SD: 0.34; 95% CI: -2.14, 
1.45). 
Exploratory neuropathology sample-SDS:  
In the autopsy subsample, 21 patients were neuropathologically diagnosed with AD and 15 with 
DLB. All AD cases were pathologically confirmed to have AD, including one case with 
coexisting Lewy bodies. All DLB cases were confirmed to have DLB, with varying degrees of 
neurofibrillary tangle pathology.15 66.6% (n=8/12) of the APOE-ε4 non-carriers had CAA 
compared to 76% (n=16/21) of APOE-ε4 carriers. 64% (n=9/14) of heterozygous APOE-ε4 
carriers had CAA, whereas 100% (n=7/7) of the homozygous APOE-ε4 carriers had CAA. 
However, differences across these groups were not significant (Fisher’s exact test p-
value=0.123). 50% (n=6/12) of patients with ɛ3-ɛ3genotype had CAA, 50% (n=1/2) of the ɛ3-ɛ2 
patients, 39% (n=8/13) of ɛ3-ɛ4 patients, and 100% (n=7/7) of the ɛ4-ɛ4 patients had CAA. 
There were no patients with ɛ2-ɛ2 genotype. 
 




Characteristics of the study sample are summarized in Table 5. We did not find any differences 
in characteristics and WMH volumes between APOE-ε4 carriers and non-carriers except that 
carriers were significantly younger than non-carriers (p-value 0.02). 
Comparison of study characteristics by allele dosage showed that APOE-ε4 homozygotes were 
younger than heterozygotes and non-carriers (ANOVA p-value=<0.001; Table 5). WMH 
volumes did not differ by allele-dosage. Table 6 summarizes the neuropsychological test scores 
by APOE-ε4 carrier status for ADNI-I. 
In the CFA, single confirmatory factor models for all three cognitive factors tested, showed an 
excellent fit to the data: attention/executive (CFI=0.999, RMSEA=<0.0001, SRMR=0.004); 
learning/memory (CFI=0.996, RMSEA=0.06, SRMR=0.019); language (CFI=1.00, 
RMSEA=<0.0001, SRMR=<0.0001). 
In the full model (N=198), WMH volume was associated with attention/executive functions (p-
value <0.001), but not with memory or language. No interaction was observed between WMH 
and APOE-ε4 for executive functions (p-value 0.069), memory (0.97), or language (0.34). 
In APOE-ε4 carriers only, greater WMH volume was associated with worse performance on the 
attention/executive functions and language, but not with memory (Table 7). 
As in the SDS, WMH volume was associated with executive functions in APOE-ε4 
heterozygotes (difference per SD: -0.20; 95% CI: -0.30, -0.09) but not in homozygotes 
(difference in score: -0.23; 95% CI: -0.47, 0.002). For language, however, effect estimates for 




Meta-analyses of estimates from SDS and ADNI-I showed a strong association of WMH with 
attention/executive functions (difference per SD: -0.19; 95% CI: -1.27, -0.11; p-value: 2.117x10-
3), learning/memory (difference per SD: -1.02; 95% CI: -1.79, -0.25; p-value: 0.009) and 
language (difference per SD: -0.75; 95% CI: -1.19, -0.31; p-value: 0.0009) in carriers, with no 
effects seen in non-carriers. No heterogeneity was observed between the two studies and 
variance in effect-estimates attributable to heterogeneity for all domains was ~0%. 
 
DISCUSSION 
Our findings imply that in carriers of the APOE-ε4 allele, WMH burden, a marker of cerebral 
SVD, is inversely associated with cognitive performance, whereas no such effect was seen in 
non-carriers. Moreover, this was consistent across the AD/DLB spectrum in contrast to previous 
studies.4,29 After excluding DLB patients from the SDS sample, the associations of WMH 
volume with executive functions, memory, and language remained significant. Cerebral SVD can 
be considered a relevant co-pathology across the AD/DLB spectrum. Because of the high 
frequency of coexisting neurodegenerative pathologies,33,34 shared risk factors and pathologies 
cannot be disentangled if samples are segregated on clinical diagnoses alone.15 
Although a unified model with an interaction term is the optimum method to test effect-
modification, an important limitation is that more statistical power is required than for 
association testing, and thus false negative results may be seen in smaller samples. The 
documented strong biological effects of APOE-ε428 formed the basis of our a priori hypothesis, 
i.e. greater WMH burden relates more strongly with worse cognition in APOE-ε4 carriers, which 




interaction results. Given the strong biological rationale, limited sample size, and a significant 
interaction observed for the language domain, we believe that this was a valid approach, which 
has also been used by other groups.35,36 However, studies in larger sample sizes are warranted. 
The replication of worse executive functions and language in relation to higher WMH in ADNI-I 
APOE-ε4 carriers, is remarkable, and also validates our findings. Notably, ADNI-I comprises 
cases with relatively lower WMH burden compared to SDS,17 and this finding indicates that 
APOE-ε4 may contribute to worse cognitive performance in those with even a lower burden of 
cerebral SVD. Effect estimates for memory did not reach significance in the ADNI-I sample 
which might be explained by lack of power. However, the significant association of greater 
WMH volume with cognitive impairment across all three domains observed in the meta-analysis 
supports our primary findings. 
While our data supported our hypothesis, it failed to show an allele dosage effect. This could be 
a result of the small size of the homozygous group; however, the similar pattern of results in both 
SDS and ADNI-I suggests that this is not just a power issue. There are several possible 
considerations. The first consideration is age and cardiovascular risk factor distribution. 
Although in both study samples, age did not differ between APOE-ε4 carriers and non-carriers; 
among carriers, homozygotes were younger. In the SDS sample, the homozygous group was not 
only younger, but it also had less WMH and cardiovascular risk factor burden, which might 
explain our findings. Second, since we adjusted for these pertinent confounders, a complex 
interaction may exist between APOE-ε4, vascular risk factors, WMH, and cognition.37,38 
Specifically, a higher vascular risk factor burden combined with APOE-ε4 genotype results in 
reduced white matter integrity and predicts faster cognitive decline.38 Third, the observed 




association of WMH and cognition becomes more apparent with advancing age and dementia 
progression.39 Increasing age becomes an important determinant of cognitive decline when 
effects of APOE-ε4 and its interactions with other risk factors are at play.40,41 
The mechanisms underlying this association may be Amyloid-beta (Aβ) dependent, Aβ 
independent, or both. In addition to causing accelerated cerebral amyloid deposition and 
impaired clearance of Aβ, APOE-ε4 can cause detrimental effects on brain through vascular 
pathways. APOE-ε4 is associated with neurovascular dysfunction, has a synergistic effect with 
atherosclerosis by disrupting cholesterol homeostasis, and also affects vessels via CAA. These 
synergistic effects can drastically compound the damaging effects of WMH in APOE-ε4 
carriers.42 Faster WMH progression rates were noted in APOE-ε4 positive AD patients and 
healthy adults, supporting our interaction hypothesis.39,43 APOE-ε4 carriers might also have more 
covert WM damage which is not detected by routine imaging,44 but is reflected as worse 
cognitive outcomes. Future large prospective studies are needed. 
WMH burden reflects a worse cerebrovascular status, potentially increasing vulnerability to 
neurodegeneration. Higher WMH volume has been associated with reduced cerebral perfusion 
both in hyperintense areas and normal appearing white matter.45 Normal appearing white matter 
surrounding WMH already exhibit subtle damage,44 and will likely develop into areas of T2 
MRI-detectable WMH. Also, neuroinflammation is a key feature in AD,46 and APOE-ε4 carriers 
have increased levels of plasma inflammatory markers compared to non-carriers, and may also 
have a differential regulation of neuroinflammatory responses compared to other APOE 




Our neuropathology data showed high agreement between our clinical diagnosis and the 
definitive pathological diagnosis. Although our data showed that 100% of homozygous APOE-ε4 
carriers had CAA compared to 64% of heterozygotes, it did not show that WMH burden was 
associated with worse cognition in people with two alleles, and should be interpreted with 
caution due to the small sample size. While we cannot deduce that worse cognitive outcomes in 
APOE-ε4 carriers with WMH are due to CAA, we can speculate that CAA is the more likely 
etiology for WMH in APOE-ε4 carriers than in non-carriers, or the likelihood of CAA increases 
with each added APOE-ε4 allele. The accelerated amyloid deposition in APOE-ε4 carriers 
together with CAA may have a multiplicative detrimental effect on cognition. Findings from a 
recent population-based study concur with our data showing accelerated WMH-related decline in 
MMSE score in APOE-ε4 carriers only. However, this study employed a microvascular lesion 
load summary score, which ranked an individual from 0 to 3 based on the absence or presence of 
WMH volume, lacunes and perivascular spaces beyond a predefined cut-off. Additionally, this 
study did not examine the effects of APOE-ε4 allele dosage on the associations of microvascular 
lesion load and MMSE. Therefore, comparisons to our results in this regard could not be made.50 
In contrast, we used quantitative WMH volume as a continuous predictor and three cognitive 
domains as outcomes rather than global cognitive score in our study. 
We examine the effect of APOE-ε4 on the association between WMH and cognition in the two 
most common neurodegenerative dementia diagnoses, i.e. AD and DLB, which is uncommon as 
most studies focus on AD. Strengths of our study include a well characterized study sample of 
dementia patients, rigorous image-processing methods validated for older adults and mixed 
dementias, comprehensive neuropsychological testing, adjusting for confounders, use of an 




However, there are certain limitations. This was a cross-sectional study and therefore causal 
inferences could not be deduced. The statistical tests in some sub-analyses, such as those in 
homozygous APOE-ε4 carriers and the autopsy sub-sample, had limited power to detect 
associations, and the null association in the non-carriers of APOE-ε4 might be a result of the 
limited sample size (power) as well. Therefore, studies with larger sample sizes are required. 
However, in an attempt to obtain more robust estimates, we conducted meta-analyses of 
estimates from SDS and ADNI, which resulted in stronger results. The SDS and ADNI-I used a 
different neuropsychological battery; however, there were similar tests available in both cohorts 
tapping into the major cognitive domains. This would not have affected our results as replication 
is more robust if performed using a different methodology to test the same research question. 
The number of patients who completed each cognitive test differed, which was related to 
dementia severity. Missing data from more severe cases might have resulted in an 
underestimation of the associations. Smoking and diabetes were not documented for most ADNI-
I participants, hence were not included as covariates; these were not significant confounders in 
the SDS sample, so we believe models in the two samples are fairly comparable. The numbers in 
the autopsy-based dataset were not sufficient to draw definitive conclusions; however they 
provided important insights and can possibly direct future research. 
APOE-ε4 may influence the association of WMH with executive functions and language across 
the spectrum of AD and DLB. Our meta-analysis results showed significant associations of 
greater WMH volume with cognitive impairment across all three cognitive domains tested. 
Information about the APOE-ε4 status of patients may be useful to understand the relative 
contributions of different pathologies to an individual’s unique dementia syndrome, and to guide 




and larger datasets. These findings emphasize the importance of WMH (as a marker of SVD) 
across the AD/DLB spectrum, and open avenues for further research to understand shared 
etiologies and risk factors across the dementias. 
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Table 1: Characteristics of the study sample, N=289 (Sunnybrook Dementia Study) 
Characteristics Descriptives 









Carriers of 1 
APOE-ɛ4 allele 
n=130 
Carriers of 2 
APOE-ɛ4 alleles 
n=37  
Age (years) 71.1 (9.6) 71.7 (10.5) 70.7 (8.9) 71.1 (9.2) 69.4 (7.7) 
Women 147 (50.9) 57 (46.7) 90 (53.9) 70 (53.8) 20 (54.0) 
Educational level (years) 13.9 (3.6) 13.9 (3.6) 13.9 (3.6) 14.1 (3.5) 13.2 (3.9) 
MMSE score 23.5 (4.1) 23.5 (4.3) 23.6 (4.0) 23.6 (4.0) 23.5 (3.9) 
DRS score 118.8 (13.4) 118.5 (14.4) 119.0 (12.8) 119.0 (13.0) 120.2 (12.1) 
Smoking 
   
  
Never 168 (58.1) 69 (56.6) 99 (59.3) 74 (56.9) 25 (67.6) 
Former  104 (36.0) 49 (40.2) 55 (32.9) 45 (34.6) 10 (27.0) 
Current 17 (5.9) 4 (3.3) 13 (7.8) 11 (8.5) 2 (5.4) 
Systolic blood pressure, mmHg 138.3 (19.7) 135.8 (20.9) 140.1 (18.6) 140.9 (19.1) 137.2 (16.2) 




Hypertension 101 (35.0) 50 (41.0) 51 (30.1) 44 (33.8) 6 (16.2) 
Diabetes mellitus type 2  25 (8.6) 12 (9.8) 13 (7.8) 13 (10) 0 # 
Clinical diagnosis of dementia 
   
  
AD + varying SVD 239 (82.7) 100 (82.0) 139 (83.2) 110 (84.6) 29 (78.4) 
DLB + varying SVD 50 (17.3) 22 (18.0) 28 (16.8) 20 (15.4) 8 (21.6) 
Raw WMH, cm3 7.5 (10.4) 8.1 (10.4) 7.2 (10.4) 7.5 (10.6) 6.1 (9.5) 
TIV adjusted WMH 6.2 (8.4) 6.7 (8.8) 5.8 (8.1) 6.0 (7.9) 5.3 (8.8) 
TIV adjusted WMH, median [IQR] 3.1 [1.1-8.1] 3.3 [1.1-8.5] 3.0 [1.0-7.8] 3.4 [1.1-8.5] 2.2 [0.9-5.6] 
Values are means (standard deviation), counts (percentage), or medians [interquartile range] 
Abbreviations: MMSE-Mini-Mental State examination; DRS-Dementia Rating Scale; AD-Alzheimer’s disease; SVD-Small vessel 




Table 2: Summary of cognitive test battery in the Sunnybrook Dementia Study 
Neuropsychological Test  n Recorded response (maximum score) Mean Score ± SD (range) 
   APOE-ɛ4 non-carriers APOE-ɛ4 carriers 
Global cognition     
MMSE 289 Score (30) 23.6±4.2 (10-30) 23.8±3.9 (11-30) 
Dementia Rating Scale 289 Total score (144) 118.4±14.4 (49-143) 119.1±12.8 (82-141) 
Attention/Executive function     
Forward Digit Span 289 Number of digits correctly repeated (12) 7.5±2.1 (3-12) 7.8±2.3 (2-12) 
Backward Digit Span 289 Number of digits correctly repeated (12) 4.6±2.0 (0-10) 5.3±2.2 (0-11) 
Trail making Test A 223 Time taken to complete the task (seconds) 90.6±83.8 (22-559) 86.4±65.4 (25-310) 
WCST 246 Number of non-perseverative errors 12.7±12.4 (1-48) 14.7±13.0 (0-47) 
Phonemic fluency 236 No of correct responses (words listed starting with letters F-A-S in 1 minute) 25.4±12.7 (1-73) 29.5±13.9 (3-76) 
Digit Symbol Substitution Task 201 Number of correct matches (133) 30.4±14.1 (2-65) 31.7±13.8 (1-62) 
Learning/Memory     
CVLT 1-5  272 Total number of words correctly recalled across five trials (75) 22.8±9.8 (4-67) 22.0±9.8 (0-50) 




CVLT-Long delay cued recall 259 Number of words correctly recalled after 20 minutes with cuing (15) 3.7±2.9 (0-14) 3.2±2.7 (0-11) 
WMS-visual reproduction-
immediate recall 
265 Number of correct responses (41) 17.7±7.7 (0-34) 17.3±7.6 (1-35) 
WMS-visual reproduction-
delayed recall 
263 Number of correct responses after a delay (41) 3.9±5.3 (0-20) 3.1±5.0 (0-22) 
Language     
Boston Naming 289 The number of spontaneous correct (30) 21.3±6.3 (0-30) 21.5±6.3 (4-30) 
Semantic Fluency 289 Number of correct responses in one minute (animal names) 10.4±4.7 (0-26) 10.9±5.1 (0-34) 
 
Abbreviations: MMSE: Mini Mental State Examination; CVLT: California Verbal Learning Test; WMS: Wechsler Memory Scale; 




Table 3: Association between white matter hyperintensities volume and factor scores by APOE-ε4 carrier status—the 
Sunnybrook Dementia Study 
 Association between WMH and cognition 
 APOE-ɛ4 non-carriers, n=122 APOE-ɛ4 carriers, n=167 
Factor Model 1 Model 2 Model 1 Model 2 
 
Difference per SD 
(95% CI) 
P-value 
Difference per SD 
(95% CI) 
P-value 
Difference per SD 
(95% CI) 
P-value 
Difference per SD 
(95% CI) 
P-value 
Attention/Executive  -0.01 (-0.19, 0.16) 0.883 0.01 (-0.10, 0.23) 0.895 -0.16 (-0.33, 0.01) 0.071 -0.18 (-0.35, -0.01) 0.034 
Learning/Memory -0.23 (-1.57, 1.11) 0.732 -0.28 (-1.69, 1.14) 0.699 -0.97 (-1.94, 0.005) 0.051 -1.07 (-2.07, -0.08) 0.034 
Language 0.15 (-0.53, 0.84) 0.653 0.17 (-0.53, 0.86) 0.634 -0.82 (-1.44, -0.19) 0.011 -0.86 (-1.51, -0.21) 0.009 
 
Model 1: adjusted for age and sex only 
Model 2: additionally adjusted for education, systolic and diastolic blood pressure, diabetes mellitus type 2, smoking status, and the 
clinical diagnosis of dementia 
Factor scores are derived from Confirmatory Factor Analysis. Tests constituting the factor scores are as follows: 
Attention/executive: Forward and backward digit span, Wisconsin Card Sorting Test (reverse coded), phonemic fluency F-A-S, trails 




Learning/memory: California verbal Learning test (CVLT) 1-5, CVLT long delay free and cued recall, and Wechsler memory scale 
visual recognition immediate and delayed recall 




Table 4: Association between white matter hyperintensities volume and factor scores by APOE-ε4 carrier status after 
excluding DLB cases—the Sunnybrook Dementia Study 
 Association between WMH and cognition 
 APOE-ɛ4 non-carriers, n=100 APOE-ɛ4 carriers, n=139 
Factor Model 1 Model 2 Model 1 Model 2 
 
Difference per SD 
(95% CI) 
P-value 
Difference per SD 
(95% CI) 
P-value 
Difference per SD 
(95% CI) 
P-value 
Difference per SD 
(95% CI) 
P-value 
Attention/Executive  0.01 (-0.18, 0.19) 0.941 0.02 (-0.17, 0.21) 0.835 -0.18 (-0.37, 0.01) 0.060 -0.20 (-0.39, -0.005) 0.044 
Learning/Memory -0.14 (-1.58, 1.30) 0.848 -0.15 (-1.69, 1.39) 0.848 -1.14 (-2.22, -0.06) 0.038 -1.21 (-2.31, -0.11) 0.031 
Language 0.15 (-0.60, 0.90) 0.688 0.19 (-0.60, 0.98) 0.633 -1.00 (-1.70, -0.31) 0.005 -1.06 (-1.78, -0.35) 0.004 
 
Model 1: adjusted for age and sex only 
Model 2: additionally adjusted for education, systolic and diastolic blood pressure, diabetes mellitus type 2, and smoking 
Factor scores are derived from Confirmatory Factor Analysis. Tests constituting the factor scores are as follows: 
Attention/executive: Forward and backward digit span, Wisconsin Card Sorting Test (reverse coded), phonemic fluency F-A-S, trails 




Learning/memory: California verbal Learning test (CVLT) 1-5, CVLT long delay free and cued recall, and Wechsler memory scale 
visual recognition immediate and delayed recall 















Carriers of 1 
APOE-ɛ4 allele 
n=91 
Carriers of 2 
APOE-ɛ4 alleles 
n=40  
Age (years) 75.1 (7.4) 76.8 (8.6) 74.3 (6.5) 75.4 (6.1) 71.8 (6.9) 
Women 84 (42.0) 34 (50.7) 50 (37.6) 40 (44.4) 16 (45.7) 
Educational level (years) 15.3 (3.0) 15.4 (3.2) 15.2 (2.9) 15.1 (3.1) 15.3 (2.4) 
MMSE score 20.7 (4.9) 20.9 (5.2) 20.7 (4.8) 20.7 (4.6) 20.5 (5.4) 
Systolic blood pressure, mmHg 133.7 (18.1) 132.7 (20.6) 134.2 (16.7) 134.1 (15.9) 134.5 (18.5) 
Diastolic blood pressure, mmHg 73.5 (10.4) 72.2 (11.4) 74.1 (9.8) 73.8 (10.0) 74.8 (9.5) 
TIV adjusted WMH 0.8 (1.5) 1.1 (2.0) 0.72 (1.2) 0.76 (1.3) 0.66 (1.1) 
TIV adjusted WMH , median [IQR] 0.31 [0.12-0.78] 0.31[0.11-0.99] 0.32[0.12-0.73] 0.28 [0.12-0.60] 0.32 [0.11-0.87] 
 
Values are means (standard deviation) or counts (percentage) or medians [interquartile range] 




Table 6: Summary of cognitive test battery in the ADNI-I study 
Neuropsychological Test  n Recorded response (maximum score) Mean Score ± SD (range) 
   APOE-ɛ4 non-carriers APOE-ɛ4 carriers 
Global cognition     
MMSE  198 Score (30) 20.9±5.2 (5-30) 20.7±4.8 (5-28) 
Attention/Executive function     
Forward Digit Span  198 Number of digits correctly repeated (14) 6.8±2.7 (0-12) 6.9±2.1 (0-12) 
Backward Digit Span   198 Number of digits correctly repeated (14) 4.4±2.1 (0-8) 4.8±2.0 (1-11) 
Trail making Test A  198 Time taken to complete the task (seconds) 71.9±42.4 (27-150) 67.6±40.2 (0-150) 
Digit Symbol Substitution Task  198 Number of correct digit symbol matches (133) 25.1±14.9 (0-53) 24.2±13.9 (0-56) 
Learning/Memory     
RAVLT1-5  198 Total number of words correctly recalled across five trials (75) 19.8±8.9 (0-38) 18.9±8.1 (0-36) 
RAVLT-delayed recall  198 Total number of words correctly recalled after a 20 minute delay (15) 6.9±4.6 (0-15) 5.2±4.1 (0-15) 
Logical Memory-immediate recall  198 Total bits of information from the story recalled immediately (25) 4.0±3.3 (0-17) 3.7±3.2 (0-13) 
Logical Memory-delayed recall  198 Total bits of information from the story recalled after a 30-minute delay (25) 1.3±2.7 (0-14) 0.9±2.0 (0-10) 




Language     
Boston Naming  198 The number of spontaneous correct (30) 21.0±8.0 (0-30) 21.1±7.1 (2-30) 
Category Fluency-animals  198 Number of correct responses in one minute (animal names) 10.6±5.4 (0-37) 11.3±5.4 (1-27) 
Category Fluency-vegetables  198 Number of correct responses in one minute (vegetable names) 7.1±3.8 (0-17) 6.4±4.0 (0-19) 
 





Table 7: Association between white matter hyperintensities volume and factor scores obtained by confirmatory factor 
analyses, the Alzheimer’s Disease Neuroimaging Initiative Phase I—ADNI-I 
 Association between WMH and cognition 
 
 APOE-ɛ4 non-carriers, n=67 APOE-ɛ4 carriers, n=131 
Factor Model 1 Model 2 Model 1 Model 2 
 Difference per SD 
(95% CI) 
P-value 
Difference per SD 
(95% CI) 
P-value 
Difference per SD 
(95% CI) 
P-value 
Difference per SD 
(95% CI) 
P-value 
Attention/Executive -0.10 (-0.22, 0.02) 0.101 -0.09 (-0.10, 0.08) 0.147 -0.19 (-0.28, -0.10) <0.001 -0.19 (-0.28, -0.10) <0.001 
Learning/Memory  -1.37 (-3.24, 0.50) 0.148 -1.27 (-3.21, 0.67) 0.196 -0.82 (-2.09, 0.45) 0.204 -0.94 (-2.19, 0.31) 0.138 
Language -0.32 (-1.10, 0.46) 0.420 -0.29 (-1.10, 0.51) 0.467 -0.60 (-1.21, 0.01) 0.055 -0.65 (-1.26, -0.03) 0.040 
 
Model 1: adjusted for age and sex only 
Model 2: additionally adjusted for education, and systolic and diastolic blood pressure 
Factor scores are derived from Confirmatory Factor Analysis. Tests constituting the factor scores are as follows: 




Learning/memory: Rey Auditory Verbal Learning Test (RAVLT) score through trials 1-5, RAVLT delayed recall, Logical memory 
immediate and delayed recall 
Language: Boston naming, category fluency animals, and category fluency vegetables 
